Fresh analysis reveals that patients who come off blockbuster GLP-1 drugs like Wegovy and Mounjaro can put back on reduced body mass much more quickly than those who halt conventional diet and exercise plans.
Research printed in a leading health publication demonstrates that while obese individuals can lose a large proportion of their total mass while undergoing treatment, the mass comes back at an average rate of 0.8 kg per month after stopping.
"People purchasing these drugs should be aware of the danger of rapid rebound weight gain when the treatment concludes," cautioned expert Dr. Susan Jebb.
That rate of recovery means a reversion to pre-treatment mass within about 18 months.
Weighing Therapies
The research, which looked at dozens of trials involving over 9,000 of patients, contrasted the outcomes of these new drugs with other pills.
The team emphasize that people who lose weight through lifestyle changes alone typically have a slower creep back—perhaps 100 grams monthly—after stopping.
The Reason for the Rapid Regain
Doctors believe the mechanism of the jabs is key to understanding the amplified rebound.
GLP-1 drugs imitate a body's own chemical called GLP-1, which moderates feelings of fullness.
"Sustained high doses of GLP-1 levels far above than normal could lead to the body to produce less of its endogenous GLP-1, and may also diminish sensitivity to its actions," noted Dr. Adam Collins, a dietetics expert.
"Withdrawal of this GLP-1 'fix' leads to appetite is unsuppressed, making overeating much more probable."
A Lifelong Disease?
Medical guidelines suggest the jabs for people with obesity-related health risks, accompanied by prescribed lifestyle changes.
A number of clinicians say that, given the significant potential of weight regain, the treatment is often ongoing.
This opinion is supported by pharmaceutical companies, who note that the findings "emphasize the chronic character of excess weight," comparing it to managing diseases like hypertension.
User Testimonies
Users who have stopped the medication describe a sudden resurgence of appetite.
"It felt as if something that goes on and you're instantly starving," said one woman.
This challenge is exacerbated if users have not adopted permanent lifestyle or habit changes during therapy.
Widespread Interest
Survey data suggest that a significant number of adults in the UK have used weight-loss jabs in the last 12 months, with desire remaining high.
- Use is greater among women compared to men.
- The 40s and 50s age group shows the greatest usage rates.
- Many access the medications through private healthcare rather than the NHS.
Finally, researchers caution that while the jabs are effective agents for shedding pounds, they are not a standalone cure and maintained weight loss likely depends on combined lifestyle management.
